Literature DB >> 11692591

Pulmonary venous obstruction requiring lobectomy for hemoptysis after a Glenn operation.

K Matsuyama1, M Matsumoto, H Ogino, T Sugita, S Yoshimura, M Matsumura.   

Abstract

Right atrial isomerism is well known to be associated with anomalous pulmonary venous drainage and a potentially dangerous sequel to pulmonary venous obstruction, and is associated with high mortality. We report a 16-month-old girl with pulmonary venous obstruction requiring lobectomy for hemoptysis after a Glenn operation. Two years after surgery, she is doing well with 80% oxygen saturation and no further episodes of hemoptysis.

Entities:  

Mesh:

Year:  2001        PMID: 11692591     DOI: 10.1007/bf02916229

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  5 in total

1.  Management and outcomes of right atrial isomerism: a 26-year experience.

Authors:  A Hashmi; R Abu-Sulaiman; B W McCrindle; J F Smallhorn; W G Williams; R M Freedom
Journal:  J Am Coll Cardiol       Date:  1998-04       Impact factor: 24.094

2.  Pulmonary venous obstruction following atrioplasty for partial anomalous pulmonary venous drainage.

Authors:  L D Voegele; E F Parker
Journal:  Chest       Date:  1987-05       Impact factor: 9.410

3.  Management and outcome of infants and children with right atrial isomerism.

Authors:  M Sadiq; O Stümper; J V De Giovanni; J G Wright; B Sethia; W J Brawn; E D Silove
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

4.  Dilatation, compensatory growth, or both after pneumonectomy during childhood and adolescence. A thirty-year follow-up study.

Authors:  C D Laros; C J Westermann
Journal:  J Thorac Cardiovasc Surg       Date:  1987-04       Impact factor: 5.209

5.  Systemic and pulmonary venous connections in visceral heterotaxy with asplenia. Diagnostic and surgical considerations based on seventy-two autopsied cases.

Authors:  M Rubino; S Van Praagh; K Kadoba; R Pessotto; R Van Praagh
Journal:  J Thorac Cardiovasc Surg       Date:  1995-09       Impact factor: 5.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.